Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02963948 · ClinicalTrials.gov registry record

A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 3

A clinical trial of Substance Abuse, sponsored by NYU Langone Health.

Completed
Registry status
113,123
Enrollment target
2
Study locations

NCT02963948: Completed study of Substance Abuse, sponsored by NYU Langone Health.

NCT02963948 is a study of Substance Abuse that has completed, run by NYU Langone Health. The registered enrollment target is 113,123 participants, above the 3,309-participant average among 58 other Substance Abuse trials with a reported enrollment target (3319% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02963948, a study of Substance Abuse, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
113,123 participants
Enrollment target
2
Study locations

Study Summary

This is a 4-phase study to implement the NIDA CDEs in primary care settings. Collecting and utilizing the CDEs in clinical practice requires a strategy for implementing screening to collect substance use information that populates the CDEs, and assisting primary care medical staff to offer appropriate interventions by providing clinical decision support (CDS) and a mechanism for making referrals to addiction treatment. Investigators aim to maximize the efficient adoption of screening, CDS, and treatment referrals by integrating all of these activities into the electronic health record (EHR). The study will be conducted at three sites, representing three large health systems. Each phase will include deliverables essential to move to the next phase, and an independent Advisory Committee will review progress and make recommendations at each transition about how best to progress to each subsequent phase. Based on progress during earlier phases, the Advisory Committee may recommend expansion to additional clinics or health systems during the second part of Phase 4.

Primary Outcome

% patients presenting for primary care visits who were screened in the past 12 months

Conditions Studied

Interventions

  • BEHAVIORAL Meetings with implementation leader(s)
  • BEHAVIORAL the SAAS survey
  • BEHAVIORAL Patient surveys

Study Locations (2)

Massachusetts

  • Massachusetts General Hospital - Boston

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 113,123 participants
Start Date 2018-02-28
Est. Completion 2019-09-09
NYU Langone Health

1,164 total trials

What the finished NCT02963948 record still lists

NCT02963948 is an observational study that tracks outcomes without assigning an intervention. Its 113,123 participants enrollment target places it among the larger protocols in the corpus, above the 3,309-participant average among 58 other Substance Abuse trials with a reported enrollment target (3319% higher).

The record links to 1 condition, with Substance Abuse appearing as the primary indexed condition, and to 3 interventions - of which Meetings with implementation leader(s) is the first listed.

NCT02963948 reports a single indexed study location in Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT02963948 about?

NCT02963948 is a clinical study titled "A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 3". This is a 4-phase study to implement the NIDA CDEs in primary care settings. Collecting and utilizing the CDEs in clinical practice requires a strategy for implementing screening to collect substance use information that populates the CDEs, and assisting primary care medical staff to offer appropria...

What is the current status of trial NCT02963948?

This trial is currently completed. The enrollment target is 113,123 participants. The study started on 2018-02-28. Estimated completion is 2019-09-09.

What conditions does trial NCT02963948 study?

This clinical trial studies the following conditions: Substance Abuse.

What interventions are being tested in trial NCT02963948?

The interventions under investigation include: Meetings with implementation leader(s) (BEHAVIORAL), the SAAS survey (BEHAVIORAL), Patient surveys (BEHAVIORAL).

Who is sponsoring clinical trial NCT02963948?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02963948 being conducted?

This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance Abuse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02963948's enrollment target sits among peer trials

113,123 1st of 58 higher than 58 of 58 other Substance Abuse trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Substance Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06251323 · 119,680 participants · NA

    Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)

  • NCT03897374 · 120,000 participants

    Strategic Targeting for Optimal Prevention of Cancer

  • NCT06608758 · 120,000 participants

    End Diagnostic Overshadowing:Addressing Ableism in Diagnoses

  • NCT05804188 · 105,000 participants

    CRICKET: Critical Events in Anaesthetised Kids Undergoing Tracheal Intubation

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02963948, the US trial registry maintained by the National Library of Medicine. NCT02963948 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.